Rationale for combination therapy with galantamine and memantine in Alzheimer's disease

Journal of Clinical Pharmacology

Volumn 46, Issue SUPPL. 7, 2006, Pages

  Grossberg, George T ^a   Edwards, Keith R ^b   Zhao, Qinying ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alzheimer's disease; Combination therapy; Donepezil; Galantamine; Memantine

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; COGNITION; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; FATIGUE; HUMAN; INSOMNIA; MUSCLE HYPERTONIA; NAUSEA; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; HUMANS; INDANS; MEMANTINE; NOOTROPIC AGENTS; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SEVERITY OF ILLNESS INDEX;

EID: 33745102766     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006288735     Document Type: Review

References (32)

1. Bird TD. Alzheimer's disease and other primary dementias. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill; 1998:2348-2356.
2. Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 1990;4:2745-2752.
3. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology. 1999;38:735-767.
4. Tariot P. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2001;2:2027-2049.
5. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21:453-478.
6. Woodruff-Pak DS, Vogel RW III, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA. 2001;98:2089-2094.
7. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol Scand Suppl. 2000;176:68-73.
8. Santos MD, Alkondon M, Pereira EFR, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol. 2002;61:1222-1234.
9. Michaels RL, Rothman SM. Glutamate neurotoxicity in vitro: antagonist pharmacology and intracellular calcium concentrations. J Neurosci. 1990;10:283-292.
10. Parsons CG, Danysz W, Bartmann A, et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 1999;38:85-108.
11. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol. 1993;33:403-407.
12. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
13. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs. 2003;17:641-652.
14. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. The Memantine Study Group. JAMA. 2004;291:317-324.
15. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269-2276.
16. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
17. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. The Galantamine International-1 Study Group. Br Med J. 2000;321:1445-1449.
18. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61:252-256.
19. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390-396.
20. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with "advanced moderate" Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003;15:79-87.
21. Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S. Galantamine provides broad benefits in patients with "advanced moderate" Alzheimer's disease (MMSE ≤ 12) for up to six months. Int J Clin Pract. 2002;56:509-514.
22. Feldman H, Sauter A, Donald A, et al. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15:89-95.
23. Feldman HH, van Baelen B, Kavanagh SM, Torfs KE. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord. 2005;19:29-36.
24. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20:777-789.
25. Wenk GL, Quack G, Moebius H-J, Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000;66:1079-1083.
26. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol. 2005;45:519-528.
27. Micuda S, Mundlova L, Anzenbacherova E, et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol. 2004;60:583-589.
28. Namenda [package insert]. St. Louis, Mo: Forest Pharmaceuticals; 2003.
29. Razadyne [package insert]. Titusville, NJ: Ortho-McNeil Neurologics; 2005.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
31. Shua-Haim JR, Smith J, Pass M, Patel P. Safety, tolerability, and caregiver's impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer's disease [abstract P1-392]. Poster presented at: the American Psychiatric Association 2004 Annual Meeting; July 17-22, 2004; Philadelphia, Pa.
32. Ramaswamy K. Safety of galantamine-memantine combination treatment for mild to moderate Alzheimer's disease. Poster presented at: the 57th Institute on Psychiatric Services; October 5-9, 2005; San Diego, Calif.